{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-016880","form_type":"8-K","ticker":"AMLX","cik":"0001658551","company_name":"Amylyx Pharmaceuticals, Inc.","filed_at":"2022-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.561071+00:00","generated_at":"2026-06-24T00:53:57.766044+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Amylyx reports Q2 net loss $54.1M; ALBRIOZA launched in Canada; FDA PDUFA Sept 29","bullets":["Net loss of $54.1M ($0.93/sh) vs $21.9M ($3.41/sh) in Q2 2021; cash $206.7M at quarter end.","ALBRIOZA (AMX0035) commercially launched in Canada on July 29, 2022 – first product launch.","FDA Advisory Committee meeting for ALS NDA scheduled Sept 7, 2022; PDUFA action date Sept 29, 2022.","EU MAA under review; EMA decision expected first half 2023, with launch prep underway.","R&D expense $24.3M (up from $10.9M); G&A expense $30.0M (up from $7.7M) driven by commercial readiness."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-016880","json":"https://secwatch.observer/filing/0000950170-22-016880.json","markdown":"https://secwatch.observer/filing/0000950170-22-016880.md","text":"https://secwatch.observer/filing/0000950170-22-016880.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658551/000095017022016880/0000950170-22-016880-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658551/000095017022016880/amlx-20220811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T00:53:57.766044+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}